Data Year:

For its 2024 fiscal year, SUPERNUS PHARMACEUTICALS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Jack A. Khattar
Chief Executive Officer, President & Secretary
Total Compensation $12,648,993 View details Pay Rank By Title In Biotechnology industry #72 View more
Padmanabh P. Bhatt Ph.D.
Senior Vice President, Intellectual Property, Chief Scientific Officer
Total Compensation $1,277,980 View details Pay Rank By Title In Biotechnology industry #16 View more
Timothy C. Dec
Senior Vice President, Chief Financial Officer
Total Compensation $2,294,848 View details Pay Rank By Title In Biotechnology industry #211 View more
Jonathan Rubin MD
Senior Vice President, Chief Medical Officer Research and Development
Total Compensation $1,484,083 View details Pay Rank By Title In Biotechnology industry #224 View more
Frank Mottola
Senior Vice President, Quality GMP Operations, Information Technology and Regulatory Affairs
Total Compensation $1,345,424 View details Pay Rank By Title In Biotechnology industry #6 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at SUPERNUS PHARMACEUTICALS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. SUPERNUS PHARMACEUTICALS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. SUPERNUS PHARMACEUTICALS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Jack A. Khattar
Chief Executive Officer, President & Secretary
Total Cash $1,832,359 Equity $10,766,439 Other $50,195 $12,648,993
Padmanabh P. Bhatt Ph.D.
Senior Vice President, Intellectual Property, Chief Scientific Officer
Total Cash $604,468 Equity $620,053 Other $53,459 $1,277,980
Timothy C. Dec
Senior Vice President, Chief Financial Officer
Total Cash $715,981 Equity $1,522,707 Other $56,160 $2,294,848
Jonathan Rubin MD
Senior Vice President, Chief Medical Officer Research and Development
Total Cash $660,030 Equity $773,779 Other $50,274 $1,484,083
Frank Mottola
Senior Vice President, Quality GMP Operations, Information Technology and Regulatory Affairs
Total Cash $518,430 Equity $773,779 Other $53,215 $1,345,424
For its 2024 fiscal year, SUPERNUS PHARMACEUTICALS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Jack A. Khattar CEO Pay $17,848,004 Median Employee Pay $166,121 CEO Pay Ratio 107:1
For its 2024 fiscal year, SUPERNUS PHARMACEUTICALS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Bethany L. Sensenig Total Cash $355,188
Carrolee Barlow, M.D., Ph.D. Total Cash $368,688
Charles W. Newhall, III Total Cash $399,688
Frederick M. Hudson Total Cash $377,688
Georges Gemayel Total Cash $381,188
John M. Siebert, Ph.D. Total Cash $351,448
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.